>>>Biotechperle Multicell Technologies Inc<<< - 500 Beiträge pro Seite

[BIOMIRA]

MultiCell Technologies Obtains Patent Protection in Several European Countries for Treatment of Autoimmune Diseases
WEDNESDAY, NOVEMBER 29, 2006 6:30 AM
- BusinessWire

MCET
0.28 +0.02 News [/red]


SAN DIEGO, Nov 29, 2006 (BUSINESS WIRE) -- MultiCell Technologies, Inc. (MCET) , developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced it has obtained patent protection for their latest issued European patent in several countries, including France, Germany, Switzerland, U.K., Ireland, Belgium, Luxembourg and Monaco. This patent covers next generation technology from MCET, targeting multibillion-dollar medical marketplace segments, including a range of serious autoimmune disorders such as type-1 diabetes and multiple sclerosis.

The patent, which was issued last month by the European Patent Office, is a milestone validation of the Company's business strategy to obtain broad, worldwide protection of its advanced immune modulation technologies and intellectual property. The patent has helped push the Company's IP portfolio past the 70 issued or pending patent threshold.

MultiCell is leveraging its breakthrough technology platforms to develop a new generation of therapeutic candidates which stimulate or suppress the immune system to treat such conditions as multiple sclerosis, type-1 diabetes, virally caused cancers, and infectious disease.

"From its inception, MultiCell has been committed to competing on the international stage," said Dr. Stephen Chang, Chief Executive Officer of MultiCell Technologies. "We believe the issuance of the patent by several European nations further validates our technology and continues to build value for our shareholders."

The patent, "Compositions for Treating Autoimmune Disease", leverages MultiCell's proprietary platform technologies for modulating the immune response to treat a range of serious diseases.

The newly issued patent is related to compositions for the effective presentation of immunosuppressive factors that are useful for the treatment of various disorders. The Company's technology platforms include Toll-like Receptor signaling and T-cell targeting to modulate both the innate and adaptive immune systems. These technologies enable the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. MultiCell's therapeutic pipeline includes drug candidates some of which are in various advanced stages of human clinical trials. These therapies include:

-- MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a Phase II clinical trial and demonstrated significant efficacy in reducing chronic fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world.

-- MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. MCT-175 successfully ameliorated the disease in animal models.

-- MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models.

-- MCT-465 in an adjuvant therapy for the treatment of virus infection and cancer. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models. MCT-465 in preclinical studies successfully eliminated certain types of tumors in animal models.

The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics.

For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html…

[BIOMIRA]

webseite

http://www.multicelltech.com/

[BIOMIRA]

MultiCell Technologies Fulfills Upfront License Fee Payment Obligation to Amarin Neuroscience for MCT-125
FRIDAY, DECEMBER 15, 2006 6:30 AM
- BusinessWire

MCET
0.26 +0.025 News


Enter Symbol:


Enter Keyword:



SAN DIEGO, Dec 15, 2006 (BUSINESS WIRE) -- MultiCell Technologies, Inc. (MCET) , developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced that the Company has completed payment of all upfront license fees related to its acquisition of MCT-125, a breakthrough drug candidate being developed as a treatment for primary chronic fatigue associated with multiple sclerosis (MS).

The payment was completed pursuant to the terms of the amended license agreement with Amarin Neuroscience Ltd. MultiCell estimates MCT-125 could generate up to $3 billion in cumulative worldwide sales during the time MCT-125 is under patent protection. If such revenue forecasts are realized by MCT-125, under the terms of the agreement, Amarin could receive up to $275 million in milestone payments and cumulative royalty payments during the same period.

"MCT-125 is one of our leading therapeutic candidates because it promises to be among the first treatments for the debilitating effects of chronic fatigue caused by multiple sclerosis," said Dr. Stephen M. Chang, Chief Executive Officer of MultiCell Technologies.

MCT-125 targets fatigue associated with MS, an autoimmune disease in which immune cells attack and destroy the myelin sheath protecting neurons in the brain and spinal cord. About two million people worldwide are afflicted with MS, and approximately 70 percent of them report fatigue as the worst symptom of their disease.

In a 138 patient, multi-center, double-blind placebo controlled Phase II clinical trial conducted in the UK by Amarin, MCT-125 (then known as LAX-202) demonstrated efficacy in significantly reducing the levels of fatigue, with few if any side effects, in all MS patient populations enrolled in the study including relapse-remitting, secondary progressive and primary progressive.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system.

MultiCell's therapeutic pipeline includes drug candidates some of which are in various advanced stages of human clinical trials. These therapies include:

-- MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a Phase II clinical trial and demonstrated significant efficacy in reducing chronic fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world.

-- MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. MCT-175 successfully ameliorated the disease in animal models.

-- MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models.

-- MCT-465 in an adjuvant therapy for the treatment of virus infection and cancer. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models. MCT-465 in preclinical studies successfully eliminated certain types of tumors in animal models.

The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics.

For more information about MultiCell Technologies, please visit http://www.multicelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell.

[BIOMIRA]

MultiCell Technologies Announces Progress for MCT-125's Anticipated Phase IIb Clinical Trial
Meeting with British Health Authorities Allows Company to Further Clinical Trials for Lead Therapeutics Program Targeting Multibillion Dollar Worldwide Market
Print
E-mail
Disable live quotes
RSS
Digg it
Del.icio.us

Last Update: 3:30 AM ET Feb 6, 2007

SAN DIEGO, Feb 06, 2007 (BUSINESS WIRE) -- MultiCell Technologies, Inc. (MCET :
multicell technologies inc com new
News , chart, profile, more
Last: 0.21+0.01+2.44%
12:27am 02/06/2007
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
MCET0.21, +0.01, +2.4% ) , developing first-in-class drugs based on advanced immune system modulation technologies, announced today it has received the formal Minutes from its December 1, 2006 milestone meeting with the Medicines and Healthcare Products Regulatory Agency UK (MHRA). The MHRA meeting cleared the way for MultiCell to prepare and submit the Clinical Trial Authorization (CTA) application, retain the MS centers where the clinical study will be conducted, and complete the manufacturing and formulation procedures for the Company's lead therapeutics program, MCT-125.
If MCT-125 is approved for the treatment of fatigue in MS patients by the MHRA, the FDA, and other such regulatory agencies, and is successfully commercialized, MultiCell estimates MCT-125 could generate up to $3 billion in cumulative worldwide sales during the time MCT-125 is under patent protection.
"The MHRA was very helpful in clarifying that our current preclinical data package and proposed clinical trial design is acceptable, which allows us to prepare and file our CTA application," said Dr. Stephen Chang, President and Chief Executive Officer of Multicell Technologies. "The results from this meeting are significant since MHRA stated we do not have to conduct additional preclinical testing of MCT-125 prior to filing our application requesting allowance to proceed with our planned Phase IIb clinical trial."
The purpose of the meeting with MHRA was to present the Company's proposed clinical development plan for MCT-125 for the treatment of chronic fatigue in multiple sclerosis (MS) patients, and to seek guidance from MHRA with respect to the proposed Phase IIb clinical trial design and accompanying preclinical data package.
In an earlier 138 patient, multi-center, double-blind placebo controlled Phase II clinical trial conducted in the UK by Amarin Corporation, MCT-125 (then known as LAX-202) demonstrated efficacy in reducing the levels of fatigue in MS patients enrolled in the study. MCT-125 proved to be effective within 4 weeks of the first daily oral dosing, and showed efficacy in MS patients who were moderately as well as severely affected. MCT-125 demonstrated efficacy in all MS patient sub-populations including relapsing-remitting, secondary progressive and primary progressive.
MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious diseases, including multiple sclerosis, type-1 diabetes, influenza, and cancer.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system.
MultiCell's therapeutic pipeline includes drug candidates some of which are in various advanced stages of human clinical trials. These therapies include:
-- MCT-125 for the treatment of chronic fatigue in MS patients.
-- MCT-175 for the treatment of relapsing-remitting MS.
-- MCT-275 for the treatment of type-1 diabetes.
-- MCT-465 in an adjuvant therapy for the treatment of virus infection and cancer.
The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs. For more information about MultiCell Technologies, please visit http://www.multicelltech.com.
For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell.
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development of MCT-125. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize MCT-125 as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
SOURCE: MultiCell Technologies, Inc.
MultiCell Technologies, Inc. Dr. Stephen Chang, CEO, 401-333-0610 [e-mail] Copyright Business Wire 2007 End of Story

[BIOMIRA]

Antwort auf Beitrag Nr.: 27.461.355 von BIOMIRA am 06.02.07 13:45:45

MultiCell Technologies Announces Prospective Cancer Treatment Drug
MCT-475 Targets Multibillion Dollar Worldwide Market for the Treatment of Colorectal Cancer, A Leading Cause of Death Among Cancer Patients
Print
E-mail
Disable live quotes
RSS
Digg it
Del.icio.us

Last Update: 3:30 AM ET Feb 15, 2007

SAN DIEGO, Feb 15, 2007 (BUSINESS WIRE) -- MultiCell Technologies, Inc. (MCET :
multicell technologies inc com new
News , chart, profile, more
Last: 0.200.000.00%
12:24am 02/15/2007
Delayed quote data
Add to portfolio
Analyst
Create alert
Insider
Discuss
Financials
Sponsored by:
MCET0.20, 0.00, 0.0% ) , developing first-in-class drugs based on advanced immune system modulation technologies, announced today it has reached a developmental milestone to advance its colorectal cancer lead therapeutic candidate to preclinical development status. MCT-475 is indicated as a prospective treatment for metastatic colorectal cancer, the third leading cause of death among both men and women in the United States. MCT-475 is a patent pending antigen-presenting immunoglobulin therapeutic which is intended to be co-administered with MCT-465, a Toll-like Receptor (TLR) agonist.
"Previously we demonstrated that co-administration of MCT-465 with our patent pending antigen-presenting immunoglobulin therapeutic IgNP prototype completely destroyed tumors, and prevented mortality and recurrence in animal models," said Dr. Stephen Chang, President and CEO of Multicell Technologies. "MCT-475 is designed to activate the adaptive immune system to target unique structural motifs located on the surface of human metastatic colorectal cancer cells, while MCT-465 is designed to activate the innate immune system through TLR signaling. Working together, MCT-475 and MCT-465 stimulate the body's immune system to target and kill metastatic colorectal cells."
Colorectal cancer is the third most common cancer in both men and women in the United States, and remains the third leading cause of death from cancer in the United States. The American Cancer Society estimates that about 145,000 new cases of colorectal cancer were reported in 2005.
According to the World Health Organization's April 2003 report on global cancer rates more than 940,000 new cases of colorectal cancer, and nearly 500,000 deaths are reported worldwide each year. The overall 5-year survival rate from the various types of colorectal cancer is approximately 60%, whereas for metastatic colorectal cancer, the 5-year survival rate is about 5%.
Risk factors for metastatic cancer include age, a diet rich in fat and cholesterol, inflammatory bowel disease, and genetic predisposition. If detected early, colorectal cancer is curable by surgery. Chemotherapy can prolong survival in patients where the disease has metastasized and reached the lymph nodes.
MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious diseases, including multiple sclerosis, type-1 diabetes, influenza, and cancer.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system.
MultiCell's therapeutic pipeline includes drug candidates some of which are in various advanced stages of human clinical trials. These therapies include:
-- MCT-125 for the treatment of chronic fatigue in MS patients.
-- MCT-175 for the treatment of relapsing-remitting MS.
-- MCT-275 for the treatment of type-1 diabetes.
-- MCT-465 an adjuvant therapy for the treatment of virus infection and cancer.
-- MCT-475 for the treatment of colorectal cancer.
The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs. For more information about MultiCell Technologies, please visit http://www.multicelltech.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development of MCT-475. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize MCT-475 as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2005, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
SOURCE: MultiCell Technologies, Inc.
MultiCell Technologies, Inc. Dr. Stephen Chang, CEO 401-333-0610 [e-mail] Copyright Business Wire 2007 End of Story

[BIOMIRA]

http://www.marketwatch.com/news/story/multicell-technologies…

good news
check it out
bio